VitaSpring Biomedical (VSBC) Risk Analysis
Risk Overview Q2, 2025
Source: the company's latest filing for the period ended Jul 31, 2025, filed Jun 17, 2026
Risk Change Over Time
- Accounting & Financial Operations - Risk 1Risks related to internal control over financial reporting
We have identified a material weakness in internal control over financial reporting. Management concluded that our internal control over financial reporting was not effective as of July 31, 2025, due to insufficient segregation of duties and lack of personnel with appropriate U.S. GAAP and SEC reporting expertise. If we fail to remediate this material weakness, we may be unable to prevent or detect material misstatements in our financial statements. If we fail to remediate this material weakness, we may be unable to timely file reports with the SEC, which could result in loss of quotation eligibility or trading market restrictions.
- Debt & Financing - Risk 2Risks related to related-party transactions and conflicts of interest
We have significant obligations to related parties, including a former officer who is involved in criminal proceedings unrelated to us. As of July 31, 2025, we owed $2,411,000 to a related-party vendor, which is owned by our former officer, and $917,020 in advances from related party, including advances made by a former Chief Executive Officer and Chairman of the Board. These obligations are unsecured, and are not subject to formal long-term repayment schedules, and may be payable on demand. The continuation of related-party financial support is not assured. On May 18, 2026, we entered into a deferred payment agreement with a related party , both parties agreed to defer collection efforts for a period of twenty -four (24) months from May 18, 2026, and the related party will not demand immediate repayment of the outstanding balance of $2,411,000. The former officer referenced above is involved in criminal proceedings relating to the alleged unauthorized use of intellectual property that was not owned by us and did not arise from our operations. We are not a party to these proceedings, and the allegations do not involve our assets, intellectual property, or current management. Nevertheless, because this individual is a creditor of us, developments in such proceedings could affect repayment discussions, restructuring negotiations, or future financing arrangements. In addition, public association with former management may result in reputational harm or investor concern. If related parties demand repayment of outstanding amounts or cease providing financial support, our liquidity and ability to continue operations could be materially adversely affected. Our governance structure may increase conflict-of-interest risk. We currently have a single director who also serves as our sole executive officer. We do not have independent directors or standing committees. We have not adopted a formal related-party transaction policy. This structure may increase the risk of conflicts of interest and reduce oversight of management decisions.
- Debt & Financing - Risk 3Risks related to capital raising and dilution
We will require substantial additional capital to execute our business strategy. We anticipate funding operations through equity offerings, convertible securities, strategic partnerships, or related-party financing. Such financings may be highly dilutive and may include terms unfavorable to existing stockholders. Our net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code. Future issuances of securities may dilute existing stockholders and depress our stock price. We may issue additional shares of common stock or securities convertible into common stock at prices below current market value. Such issuances may include warrants, anti-dilution adjustments, or other terms that adversely affect existing stockholders. Our net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code, which could reduce or eliminate their value. As of July 31, 2025, we had federal net operating loss (“NOL”) carryforwards. Our ability to utilize these NOLs to offset future taxable income, if any, may be significantly limited under Section 382 of the Internal Revenue Code of 1986, as amended (“Section 382”), if we experience an “ownership change” as defined in Section 382. In general, an ownership change occurs if the percentage of our stock owned by one or more “5-percent shareholders” increases by more than 50 percentage points over a rolling three-year testing period. Because our stock ownership is relatively concentrated and because we may issue additional equity or convertible securities in future financings, we may experience an ownership change under Section 382. An ownership change could materially limit the amount of NOLs that may be utilized annually to offset taxable income. In certain circumstances, such limitations could effectively eliminate the benefit of our NOL carryforwards. In addition, if we undergo a significant change in business operations or experience future ownership changes, our ability to utilize our NOLs could be further limited. Any such limitation could reduce the potential tax benefits available to us and may adversely affect our financial condition and results of operations. There can be no assurance that our NOL carryforwards will be available to offset future taxable income, even if we achieve profitability.
- Debt & Financing - Risk 4Risks related to our financial condition, liquidity and going concern
Substantial doubt exists regarding our ability to continue as a going concern. We have not generated revenue during the six months ended July 31, 2025. As of July 31, 2025, we had cash of $799, total assets of $17,020, total liabilities of $4,223,606, an accumulated deficit of $5,472,889, negative operating cash flows used of $1,973 and a stockholders’ deficit of $4,206,586. We have incurred recurring losses since inception and expect to continue incurring losses for the foreseeable future. Based on our current cash position and expected expenditure, we do not have sufficient liquidity to fund operations for the next twelve months without additional financing. Our financial statements have been prepared assuming we will continue as a going concern. Management has concluded that substantial doubt exists regarding our ability to continue as a going concern within twelve months from the issuance of our financial statements. Our independent registered public accounting firm has included a going concern explanatory paragraph in prior audit reports. We have no committed financing arrangements and no revenue-generating operations. Our ability to continue operations depends entirely upon raising additional capital or obtaining continued financial support from related parties. There can be no assurance that such capital will be available on acceptable terms, if at all. If we are unable to secure adequate funding, we may be forced to significantly curtail or cease operations, seek protection under applicable insolvency laws, or liquidate our assets. Our liabilities substantially exceed our assets, which may impair our ability to obtain financing and satisfy uplisting requirements. Our negative stockholders’ equity position may adversely affect investor confidence and impair our ability to obtain financing on favorable terms. Certain trading platforms and exchanges impose minimum stockholders’ equity requirements. Our current financial condition may limit our ability to satisfy such requirements, thereby restricting our ability to uplist our common stock to OTCQB or a national securities exchange. We may not be able to satisfy our obligations as they become due. A substantial portion of our liabilities consists of unsecured obligations to related parties and vendors. These obligations may be payable on demand. If creditors demand repayment or decline to extend payment terms, we may be unable to satisfy such obligations when due, which could result in default, litigation, or insolvency proceedings. To date, no formal demand for repayment has been made.
- Corporate Activity and Growth - Risk 512risks related to our development-stage status and business strategy
We are not currently conducting commercial operations, but we have had a history of revenue generation. Although we describe a long-term strategy involving regenerative medicine technologies, including potential stem-cell and exosome-based applications, we are not currently conducting commercial manufacturing, distribution, or revenue-generating activities. We did not incur research and development expenses in the current period ended July 31, 2025, or fiscal year ended January 31, 2025, have not initiated clinical trials, and have not obtained regulatory approvals. Our limited operating history makes it difficult for investors to evaluate our prospects. As of the date of this Quarterly Report, we are not actively developing, manufacturing, or marketing any products. Our business model is speculative and subject to significant execution risk. ·Our future success depends on numerous factors, including: ·Securing sufficient capital; ·Recruiting qualified personnel; ·Obtaining regulatory approvals; ·Protecting intellectual property; ·Establishing manufacturing capabilities; ·Entering into strategic partnerships; ·Achieving market acceptance. Each of these elements involves significant uncertainty. Failure in any of these areas could materially adversely affect our business. We may change our business strategy. Given our financial condition and development-stage status, we may revise or modify our business strategy. Such changes may expose us to additional risks and uncertainties and may not result in successful operations.
Risk Highlights Q2, 2025
Risk Word Cloud
Risk Factors Full Breakdown - Total Risks 11
- Accounting & Financial Operations - Risk 1AddedRisks related to internal control over financial reporting
We have identified a material weakness in internal control over financial reporting. Management concluded that our internal control over financial reporting was not effective as of July 31, 2025, due to insufficient segregation of duties and lack of personnel with appropriate U.S. GAAP and SEC reporting expertise. If we fail to remediate this material weakness, we may be unable to prevent or detect material misstatements in our financial statements. If we fail to remediate this material weakness, we may be unable to timely file reports with the SEC, which could result in loss of quotation eligibility or trading market restrictions.
See a full breakdown of risk according to category and subcategory. The list starts with the category with the most risk. Click on subcategories to read relevant extracts from the most recent report.
